Table 1 Patient demographics and baseline characteristics by ABC DLBCL, GCB DLBCL, and in the overall cohort.
ABC DLBCL n = 19 | GCB DLBCL n = 30 | Overall cohort N = 67a | |
|---|---|---|---|
Age (years), median (range) | 72.0 (41–84) | 67.0 (32–85) | 69.0 (25–93) |
Age ≥65 years, n (%) | 15 (78.9) | 17 (56.7) | 40 (59.7) |
Male, n (%) | 11 (57.9) | 17 (56.7) | 39 (58.2) |
ECOG performance status score, n (%) | |||
0 | 5 (26.3) | 8 (26.7) | 15 (22.4) |
1 | 11 (57.9) | 16 (53.3) | 38 (56.7) |
2 | 3 (15.8) | 6 (20.0) | 14 (20.9) |
Histology of tumor, n (%) | |||
DLBCL transformed from FL | 3 (15.8) | 9 (30.0) | 14 (20.9) |
DLBCL not otherwise specified | 16 (84.2) | 21 (70.0) | 51 (76.1) |
EBV-positive DLBCL of the elderly | 0 | 0 | 1 (1.5) |
T-cell/histocyte-rich large B-cell lymphoma | 0 | 0 | 1 (1.5) |
Stage at study entry, n (%) | |||
I | 0 | 3 (10.0) | 3 (4.5) |
II | 0 | 6 (20.0) | 9 (13.4) |
III | 4 (21.1) | 7 (23.3) | 11 (16.4) |
IV | 15 (78.9) | 14 (46.7) | 44 (65.7) |
Median time from initial diagnosis to start of study treatment, months (range) | 16.8 (1.4–123) | 41.4 (0.7–192) | 17.1 (0.7–192) |
Median time since first progression, months (range) | 3.0 (0.2–60.5) | 6.9 (0.7–184) | 4.3 (0.2–184) |
Median time from most recent progression to start of study treatment, months (range) | 0.8 (0.2–3.0) | 1.3 (0.2–6.2) | 5.0 (0.2–6.2) |
Median prior anticancer therapy lines, n (range) | 2 (1–5) | 3.5 (1–13) | 3 (1–13) |
Median time since last systemic anticancer therapy, months (range) | 1.7 (0.7–118) | 1.6 (1.0–68.5) | 1.9 (0.7–118) |
Refractory against last systemic anticancer therapy, n (%) | |||
Yes | 15 (78.9) | 24 (80.0) | 52 (77.6) |
No | 4 (21.1) | 6 (20.0) | 15 (22.4) |
